clinical trial · NCT06333704
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
ModernaTX, Inc.·—·active not recruiting·n = 4,207
SARS-CoV-2SPIKEVAX Bivalent BA.1SPIKEVAX Bivalent BA.4/5SPIKEVAX XBB.1.5SPIKEVAX JN.1
brief summary
The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.
started
Mar 10, 2023
primary completion
Mar 29, 2029
completion
Mar 29, 2029
last updated
Apr 16, 2026
official title
A Multi-centre, Prospective, Observational Post-marketing Surveillance to Investigate the Long-term Safety of SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE Under Routine Clinical Care in Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol